Adult Immunization Schedule
Recommendations for Ages 19 Years or Older, United States, 2023
< < Back to Adult Immunization Schedule by Age Group
¶ = Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of past infection
§ = Recommended vaccination for adults with an additional risk factor or another indication
± = Recommended vaccination based on shared clinical decision-making
⇒ = No recommendation/Not applicable
Vaccine | 19-26 years | 27-49 years | 50-64 years | ≥65 years | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
COVID-19 ![]() |
2- or 3- dose primary series and booster (see notes)¶ | |||||||||||
Influenza inactivated (IIV4) or Influenza recombinant (RIV4) ![]() |
¶1 dose annually OR¶ | |||||||||||
![]() Influenza live attenuated (LAIV4) ![]() |
1 dose annually¶ | ⇒ | ||||||||||
Tetanus, diphtheria, pertussis (Tdap or Td) ![]() |
1 dose Tdap each pregnancy; 1 dose Td/Tdap for wound management (see notes)§ | |||||||||||
1 dose Tdap, then Td or Tdap booster every 10 years¶ | ||||||||||||
Measles, mumps, rubella (MMR) ![]() |
1 or 2 doses depending on indication (if born in 1957 or later)¶ |
For healthcare personnel, (see notes)⇒ |
||||||||||
Varicella (VAR) ![]() |
2 doses (if born in 1980 or later)¶ |
¶ | § | 2 doses§ | ||||||||
Zoster recombinant (RZV) ![]() |
2 doses for immunocompromising conditions (see notes)§ | 2 doses¶ | ||||||||||
Human papillomavirus (HPV) ![]() |
2 or 3 doses depending on age at initial vaccination or condition¶ | 27 through 45 years± | ± | ⇒ | ⇒ | ⇒ | ||||||
Pneumococcal (PCV15, PCV20, PPSV23) ![]() |
1 dose PCV15 followed by PPSV23 OR 1 dose PCV20 (see notes)§ |
See Notes¶ | ||||||||||
See Notes± | ||||||||||||
Hepatitis A (HepA) ![]() |
2, 3, or 4 doses depending on vaccine§ | |||||||||||
Hepatitis B (HepB) ![]() |
2, 3, or 4 doses depending on vaccine or condition¶ | ¶ | ¶ | § | § | |||||||
Meningococcal A, C, W, Y (MenACWY) ![]() |
1 or 2 doses depending on indication, see notes for booster recommendations§ | |||||||||||
Meningococcal B (MenB) ![]() |
§ | 2 or 3 doses depending on vaccine and indication, see notes for booster recommendations§ | ||||||||||
19 through 23 years± | § | § | ||||||||||
Haemophilus influenzae type b (Hib) ![]() |
1 or 3 doses depending on indication§ |
Administer recommended vaccines if vaccination history is incomplete or unknown. Do not restart or add doses to vaccine series if there are extended intervals between doses. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.
Notes
For vaccine recommendations for persons 18 years of age or younger, see the Recommended Child and Adolescent Immunization Schedule.
Vaccines in the Adult Immunization Schedule*
Vaccine | Abbreviation(s) | Trade name(s) |
---|---|---|
COVID-19 vaccine† | 1vCOV-mRNA | Comirnaty®/Pfizer- BioNTech COVID-19 Vaccine |
SPIKEVAX®/Moderna COVID-19 Vaccine | ||
2vCOV-mRNA | Pfizer-BioNTech COVID-19 Vaccine, Bivalent | |
Moderna COVID-19 Vaccine, Bivalent | ||
1vCOV-aPS | Novavax COVID-19 Vaccine | |
Haemophilus influenzae type b vaccine | Hib | ActHIB® Hiberix® PedvaxHIB® |
Hepatitis A vaccine | HepA | Havrix® Vaqta® |
Hepatitis A and hepatitis B vaccine | HepA-HepB | Twinrix® |
Hepatitis B vaccine | HepB | Engerix-B® Heplisav-B® PreHevbrio® Recombivax HB® |
Human papillomavirus vaccine | HPV | Gardasil 9® |
Influenza vaccine (inactivated) | IIV4 | Many brands |
Influenza vaccine (live, attenuated) | LAIV4 | FluMist® Quadrivalent |
Influenza vaccine (recombinant) | RIV4 | Flublok® Quadrivalent |
Measles, mumps, and rubella vaccine | MMR | M-M-R II® Priorix® |
Meningococcal serogroups A, C, W, Y vaccine | MenACWY-D | Menactra® |
MenACWY-CRM | Menveo® | |
MenACWY-TT | MenQuadfi® | |
Meningococcal serogroup B vaccine | MenB-4C | Bexsero® |
MenB-FHbp | Trumenba® | |
Pneumococcal conjugate vaccine | PCV15 | Vaxneuvance™ |
PCV20 | Prevnar 20™ | |
Pneumococcal polysaccharide vaccine | PPSV23 | Pneumovax 23® |
Poliovirus vaccine | IPV | IPOL® |
Tetanus and diphtheria toxoids | Td | Tenivac® Tdvax™ |
Tetanus and diphtheria toxoids and acellular pertussis vaccine | Tdap | Adacel® Boostrix® |
Varicella vaccine | VAR | Varivax® |
Zoster vaccine, recombinant | RZV | Shingrix |
New vaccines added to the Schedule since February 2023 (See Addendum)
Vaccines | Abbreviation(s) | Trade name(s) |
---|---|---|
Respiratory Syncytial Virus vaccine | RSV | Arexvy® ABRYSVO™ |
*Administer recommended vaccines if vaccination history is incomplete or unknown. Do not restart or add doses to vaccine series if there are extended intervals between doses. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.
† COVID-19, Poliovirus, and Influenza vaccines have new or updated ACIP recommendations. Please see Addendum for more details.
This schedule is recommended by the Advisory Committee on Immunization Practices (ACIP) and approved by the Centers for Disease
Control and Prevention (CDC), American College of Physicians (ACP), American Academy of Family Physicians (AAFP), American College of Obstetricians and Gynecologists (ACOG), American College of Nurse-Midwives (ACNM), American Academy of Physician Associates (AAPA), American Pharmacists Association (APhA), and Society for Healthcare Epidemiology of America (SHEA).
The comprehensive summary of the ACIP recommended changes made to the adult immunization schedule can be found in the February 10, 2023 MMWR.